Biopharmaceutical company, Silo Pharma, has announced plans to study its novel joint homing peptide in the treatment of rheumatoid arthritis.
Biopharmaceutical company Silo Pharma has carried out an animal study investigating the topical administration of ketamine for pain reduction.